Observational analysis revealed that pharmacogenomics influence treatment outcomes in breast cancer, suggesting genetic counselling is needed for low BMI patients.
AA genotype at G681A in low BMI patients showed the poorest chemotherapy response and lowest PFS (HR>1). CYP2C19 variants (AA) may serve as predictive markers for non-responsiveness towards AC-T chemotherapy in low BMI BC patients, highlighting the need for genetic counselling and nutritional support to improve treatment outcomes.
No takes yet. Share an insight, caveat, or question.
Mistry et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: